08:00 AM EDT, 06/13/2025 (MT Newswires) -- Arvinas ( ARVN ) said Friday that its experimental ARV-393 showed "significant" single-agent activity in a certain type of cell lymphoma, based on data from preclinical studies.

The results cover activity in patient-derived xenograft model of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type and PDX models of transformed follicular lymphoma.

When combined with oral small molecule inhibitors, ARV-393 showed "enhanced" antitumor activity, including tumor regressions, in cell line-derived xenograft models of high-grade B-cell lymphoma and aggressive diffuse large B-cell lymphoma, the company said.

"We believe these preclinical data potentially suggest the broad utility of ARV-393 across non-Hodgkin lymphoma subtypes with unmet need beyond DLBCL and provide a compelling rationale for considering combination strategies including chemotherapy-free approaches as we work to bring forward new therapeutic options for adult patients with lymphoma," Arvinas ( ARVN ) Chief Medical Officer Noah Berkowitz said.